GLP-1 Medications for Weight Loss: Who Qualifies & Complete Options Guide

If you have been researching weight loss options in 2026, you have almost certainly come across GLP-1 medications. These drugs have changed the space of obesity treatment over the past several years, giving millions of people a medically supervised tool that produces meaningful, sustained weight loss when combined with lifestyle changes.

But the information surrounding GLP-1 medications can be overwhelming. Which medication is right for you? Do you even qualify? How much will it cost? What should you realistically expect?

This guide answers all of those questions and more. We break down every FDA-approved GLP-1 medication for weight loss, explain exactly who qualifies, walk you through the consultation and insurance process, and provide month-by-month expectations so you know what lies ahead. If you are just starting to consider GLP-1 therapy or you are comparing specific medications, this is the most comprehensive resource available.

One important note before we begin. GLP-1 medications are not a shortcut. They are a medical treatment for a medical condition. Obesity is a chronic, relapsing disease driven by complex interactions between genetics, hormones, environment, and behavior. GLP-1 medications address the hormonal and neurological components of this disease, but they work best when combined with nutritional changes, physical activity, and ongoing medical supervision.

Let us start with the most common question: do you qualify?

GLP-1 Eligibility Criteria - Who Qualifies in 2026

The first question everyone asks is whether they qualify for GLP-1 weight loss medication. The answer depends on several factors, but the core criteria are straightforward. The FDA has established clear guidelines, and most healthcare providers follow them closely when evaluating patients.

Understanding these criteria before your consultation helps you prepare the right documentation and set realistic expectations about the process.

The BMI Requirements (30+ or 27+ with Comorbidity)

Body mass index, or BMI, is the primary screening tool used to determine GLP-1 eligibility. While BMI is an imperfect measure of health (it does not account for muscle mass, body composition, or where fat is distributed), it remains the standard metric used by the FDA, insurance companies, and prescribers for medication qualification.

There are two main pathways to qualify based on BMI.

Pathway 1: BMI of 30 or higher. If your BMI is 30 or above, you meet the primary obesity threshold for GLP-1 medication. No additional health conditions are required, though most providers will still conduct a thorough health evaluation. A BMI of 30 corresponds to roughly 30 or more pounds over what standard height-weight charts consider a healthy weight. For example, a person who is 5 feet 6 inches tall would need to weigh approximately 186 pounds or more to have a BMI of 30.

Pathway 2: BMI of 27 or higher with at least one weight-related comorbidity. If your BMI falls between 27 and 29.9, you can still qualify if you have a documented weight-related health condition. This lower threshold recognizes that even moderate excess weight can cause or worsen serious health problems in some individuals. The comorbidity must be documented in your medical records or confirmed through lab work and clinical evaluation.

some healthcare providers and telehealth platforms are beginning to consider additional metrics beyond BMI alone. Waist circumference, waist-to-hip ratio, body fat percentage, and metabolic health markers are increasingly used alongside BMI to make more nuanced eligibility decisions. However, for insurance coverage purposes, BMI remains the standard gatekeeper.

If you are unsure of your BMI, you can calculate it by dividing your weight in kilograms by your height in meters squared. Most online BMI calculators will do this math for you. Many pharmacies, gyms, and doctor offices can also measure it during a routine visit.

Qualifying Comorbidities (Diabetes, Hypertension, Dyslipidemia, Sleep Apnea, PCOS, NAFLD)

If your BMI is between 27 and 29.9, you need at least one qualifying weight-related health condition to be eligible for GLP-1 medication. These conditions are also called comorbidities, meaning they exist alongside (and are often caused or worsened by) excess body weight.

The following conditions are recognized qualifiers.

Type 2 diabetes. This is one of the most well-established comorbidities for GLP-1 eligibility. In fact, GLP-1 medications were originally developed and approved for diabetes management before their weight loss benefits were discovered. If you have type 2 diabetes or prediabetes (fasting blood glucose of 100-125 mg/dL or HbA1c of 5.7-6.4%), this qualifies you for GLP-1 treatment. Your provider may prescribe a GLP-1 that treats both conditions simultaneously.

High blood pressure (hypertension). Defined as a blood pressure reading consistently at or above 130/80 mmHg, or if you are currently taking blood pressure medication. Excess weight is a leading risk factor for hypertension, and weight loss of even 5-10% can significantly improve blood pressure readings. Many patients on GLP-1 therapy are able to reduce or eliminate blood pressure medications over time.

High cholesterol (dyslipidemia). This includes elevated LDL cholesterol (above 130 mg/dL), low HDL cholesterol (below 40 mg/dL in men or below 50 mg/dL in women), elevated triglycerides (above 150 mg/dL), or any combination of these. If you are taking a statin or other cholesterol medication, this condition is already documented. Weight loss through GLP-1 therapy has been shown to improve lipid profiles in most patients.

Obstructive sleep apnea. If you have been diagnosed with obstructive sleep apnea through a sleep study, or if you use a CPAP machine, this qualifies as a comorbidity. Sleep apnea is strongly linked to excess weight, particularly fat deposits around the neck and upper airway. Clinical trials have shown that GLP-1 medications can reduce the severity of sleep apnea and, in some cases, allow patients to stop using CPAP therapy.

Polycystic ovary syndrome (PCOS). PCOS affects approximately 10% of women of reproductive age and is closely linked to insulin resistance and weight gain. Women with PCOS often find it extremely difficult to lose weight through diet and exercise alone due to the hormonal imbalances involved. GLP-1 medications can improve insulin sensitivity, support weight loss, and may improve menstrual regularity and fertility outcomes in women with PCOS.

Non-alcoholic fatty liver disease (NAFLD). Also called metabolic dysfunction-associated steatotic liver disease (MASLD), this condition involves excess fat accumulation in the liver and is strongly associated with obesity and insulin resistance. GLP-1 medications, particularly semaglutide, have shown promising results in reducing liver fat content and improving liver function markers in clinical trials.

Cardiovascular disease history. If you have a history of heart attack, stroke, peripheral artery disease, or other cardiovascular events, and you carry excess weight, this qualifies as a comorbidity. Semaglutide has demonstrated cardiovascular risk reduction benefits in the SELECT trial, making it particularly relevant for patients with both obesity and cardiovascular risk.

Osteoarthritis. Weight-bearing joint pain caused or worsened by excess body weight is an increasingly recognized qualifying condition. Every pound of body weight places approximately four pounds of pressure on the knee joints. Significant weight loss through GLP-1 therapy can meaningfully reduce joint pain and improve mobility.

What If Your BMI Is Under 27? (Off-Label Considerations)

If your BMI is below 27, you do not meet the current FDA-approved criteria for GLP-1 weight loss medications. However, this does not mean GLP-1 therapy is never prescribed in this situation.

Off-label prescribing occurs when a doctor prescribes a medication for a use that has not been specifically approved by the FDA. Off-label prescribing is legal, common across many areas of medicine, and sometimes medically appropriate. However, it comes with important considerations for weight management.

Some healthcare providers may prescribe GLP-1 medications off-label for patients with a BMI between 25 and 26.9 who have significant metabolic dysfunction, insulin resistance, or other health concerns that would benefit from weight loss. This is more common in private practice settings and cash-pay telehealth platforms where insurance coverage is not a factor.

Important points about off-label GLP-1 use for weight loss:

• Insurance companies will almost never cover GLP-1 medications prescribed off-label for weight loss in patients who do not meet BMI criteria. You would be paying out of pocket entirely.
• The clinical trial evidence for GLP-1 medications in patients with lower BMIs is limited compared to the strong data available for patients with BMIs of 27 and above.
• Some providers and telehealth platforms will not prescribe GLP-1 medications to patients who do not meet FDA criteria, regardless of payment method.
• The risk-benefit calculation changes when treating patients with lower BMIs. The potential benefit is smaller (less weight to lose), while the side effect profile remains the same.

If your BMI is under 27 and you are concerned about your weight or metabolic health, the best approach is to have an honest conversation with your healthcare provider about all available options, which may include GLP-1 medications, other prescription weight loss drugs, or intensive lifestyle interventions.

Age Requirements (18+, Adolescent Approval for Some)

GLP-1 weight loss medications are primarily approved for adults ages 18 and older. However, the space for adolescent treatment has evolved significantly in recent years.

Adults (18 and older): All FDA-approved GLP-1 weight loss medications (Wegovy, Zepbound, and Saxenda) are approved for use in adults ages 18 and older who meet the BMI criteria described above. There is no upper age limit for GLP-1 prescribing, though providers exercise additional caution in elderly patients due to concerns about muscle mass loss and nutritional status.

Adolescents (12 to 17 years old): Wegovy received FDA approval for adolescents ages 12 and older in December 2022 based on data from the STEP TEENS trial. To qualify, adolescents must have a BMI at or above the 95th percentile for their age and sex, which corresponds to clinical obesity in pediatric populations. Saxenda is also approved for adolescents ages 12 and older. Zepbound does not currently have adolescent approval, though clinical trials are underway.

Children under 12: GLP-1 medications are not approved for children under age 12. Weight management in younger children focuses on family-based lifestyle interventions, behavioral therapy, and, in rare severe cases, referral to a pediatric obesity specialist.

Adolescent prescriptions for GLP-1 medications should ideally be managed by a pediatric endocrinologist or an obesity medicine specialist with experience treating younger patients. The decision to start GLP-1 therapy in a teenager involves careful consideration of physical maturity, psychological readiness, and family support systems.

The Qualification Process Step-by-Step

Understanding the qualification process helps you prepare and reduces the likelihood of delays or denials. Here is what the process typically looks like from start to finish.

Step 1: Initial screening. Your healthcare provider (either your primary care doctor, an obesity medicine specialist, or a telehealth provider) will record your height, weight, and calculate your BMI. They will review your medical history for qualifying comorbidities and ask about your weight loss history, including previous diet attempts, exercise habits, and any prior use of weight loss medications or programs.

Step 2: Medical evaluation. A comprehensive medical evaluation is standard before prescribing GLP-1 medications. This typically includes blood work (fasting glucose, HbA1c, lipid panel, thyroid function, kidney function, liver function), blood pressure measurement, and a review of your current medications. Some providers also check insulin levels, inflammatory markers, and vitamin levels.

Step 3: Contraindication screening. Your provider will screen for conditions that make GLP-1 medications unsafe. These include a personal or family history of medullary thyroid carcinoma, a personal history of multiple endocrine neoplasia syndrome type 2 (MEN 2), current pregnancy or plans to become pregnant within the next two months, and certain other medical conditions covered in detail later in this guide.

Step 4: Treatment discussion. If you qualify, your provider will discuss medication options, expected outcomes, potential side effects, cost considerations, and the importance of combining medication with lifestyle changes. This is your opportunity to ask questions and express any concerns or preferences.

Step 5: Prescription and prior authorization. If you and your provider agree on a treatment plan, a prescription is written. If you plan to use insurance, a prior authorization request is typically submitted at this point. This can take anywhere from a few days to several weeks depending on your insurance company. If you are paying out of pocket or using a compounding pharmacy, you can often start treatment within days.

Step 6: Pharmacy fulfillment. Once the prescription is approved, it is sent to a pharmacy for fulfillment. Brand-name medications go to a retail or specialty pharmacy. Compounded medications go to a licensed compounding pharmacy. Your first shipment typically arrives within 3 to 7 business days.

With eligibility criteria clear, let us move on to the medications themselves. Understanding what each GLP-1 option offers is essential for making an informed treatment decision.

Complete Guide to Every GLP-1 Weight Loss Medication

The GLP-1 medication space for weight loss has expanded significantly since the first option became available. Today, patients have multiple FDA-approved brand-name medications, compounded alternatives, and a promising pipeline of next-generation treatments in development. Each option has distinct advantages, limitations, and ideal patient profiles.

This section provides a detailed breakdown of every available GLP-1 weight loss medication, including clinical trial data, dosing schedules, costs, and practical considerations for each option.

Semaglutide 2.4mg (Wegovy) - Efficacy, Dosing, Pros and Cons

Wegovy is manufactured by Novo Nordisk and was approved by the FDA for chronic weight management in June 2021. It contains the same active ingredient as Ozempic (semaglutide) but at a higher maximum dose specifically optimized for weight loss rather than diabetes management.

How it works. Wegovy is a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1. It acts on receptors in the brain to reduce appetite and food cravings, slows gastric emptying to promote satiety after meals, and improves insulin sensitivity. The medication is administered as a once-weekly subcutaneous injection using a pre-filled pen device.

Clinical trial evidence. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program is the foundation of Wegovy's evidence base. The program included multiple large-scale randomized controlled trials with thousands of participants.

In the STEP 1 trial, participants without diabetes who received semaglutide 2.4mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Nearly one in three participants lost 20% or more of their body weight. The STEP 2 trial in participants with type 2 diabetes showed average weight loss of 9.6% over 68 weeks. The STEP 3 trial, which combined semaglutide with intensive behavioral therapy, showed average weight loss of 16.0% over 68 weeks.

The SELECT trial demonstrated that semaglutide 2.4mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes. This landmark finding led to an expanded FDA indication for cardiovascular risk reduction.

Dosing schedule. Wegovy uses a gradual dose escalation schedule over 16 to 20 weeks to minimize gastrointestinal side effects:

• Weeks 1-4: 0.25mg once weekly
• Weeks 5-8: 0.5mg once weekly
• Weeks 9-12: 1.0mg once weekly
• Weeks 13-16: 1.7mg once weekly
• Week 17 and beyond: 2.4mg once weekly (maintenance dose)

Some providers extend the titration period if patients experience significant side effects at any dose level. Not all patients reach the full 2.4mg maintenance dose. Some achieve satisfactory weight loss at lower doses and remain there.

Pros:

• Extensive clinical trial data with thousands of participants and long follow-up periods
• FDA-approved for both weight management and cardiovascular risk reduction
• Once-weekly dosing for convenience
• Proven efficacy in patients with and without diabetes
• Adolescent approval (ages 12+)
• Pre-filled pen device requires no mixing or measuring
• Improving insurance coverage as more plans add it to formularies

Cons:

• High cost without insurance (approximately $1,350 per month)
• Gastrointestinal side effects are common during titration
• Supply shortages have affected availability at various times
• Requires refrigeration
• Some patients plateau before reaching goal weight
• weight regain is common if the medication is discontinued

Best for: Patients seeking the most clinically validated GLP-1 option with strong insurance coverage potential, particularly those with cardiovascular risk factors. Also the preferred option for adolescent patients due to FDA approval in ages 12 and older.

For a deeper dive into semaglutide specifically, see our Complete Semaglutide Weight Loss Guide.

Tirzepatide (Zepbound) - Dual Mechanism, SURMOUNT Data

Zepbound is manufactured by Eli Lilly and was approved by the FDA for chronic weight management in November 2023. It contains tirzepatide, the same active ingredient as Mounjaro (approved for type 2 diabetes). What makes tirzepatide unique is its dual mechanism of action.

How it works. Unlike pure GLP-1 receptor agonists, tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. It activates two incretin hormone receptors simultaneously, which appears to produce greater appetite suppression and metabolic benefits than targeting GLP-1 alone. GIP receptor activation provides additional effects on fat metabolism, energy expenditure, and insulin sensitivity that complement the GLP-1 effects.

Clinical trial evidence. The SURMOUNT clinical trial program evaluated tirzepatide for weight management in multiple large-scale studies.

In the SURMOUNT-1 trial, participants without diabetes who received the highest dose of tirzepatide (15mg weekly) lost an average of 22.5% of their body weight over 72 weeks, compared to 2.4% in the placebo group. More than one in three participants on the highest dose lost 25% or more of their body weight, and more than half lost at least 20%. These are the highest weight loss numbers ever reported in a pharmaceutical clinical trial for obesity.

The SURMOUNT-2 trial in participants with type 2 diabetes showed average weight loss of 14.7% at the highest dose over 72 weeks. The SURMOUNT-3 trial, which added tirzepatide after an initial intensive lifestyle intervention period, showed enhanced results with average total weight loss exceeding 25% from baseline.

The SURMOUNT-4 trial studied weight regain after discontinuation. Participants who switched from tirzepatide to placebo after 36 weeks regained approximately half of their lost weight over the next 52 weeks, while those who continued tirzepatide maintained their weight loss and continued to lose additional weight.

Dosing schedule. Zepbound uses a gradual dose escalation similar to Wegovy:

• Weeks 1-4: 2.5mg once weekly
• Weeks 5-8: 5.0mg once weekly
• Weeks 9-12: 7.5mg once weekly (may remain here or increase)
• Weeks 13-16: 10.0mg once weekly (may remain here or increase)
• Weeks 17-20: 12.5mg once weekly (may remain here or increase)
• Week 21 and beyond: 15.0mg once weekly (maximum maintenance dose)

Not all patients titrate to the maximum 15mg dose. Many achieve significant weight loss at 10mg or 12.5mg and remain at those levels. Your provider will work with you to find the dose that balances efficacy with tolerability.

Pros:

• Highest average weight loss of any currently available medication
• Dual mechanism (GLP-1 + GIP) may provide metabolic benefits beyond pure GLP-1 agonists
• Once-weekly dosing
• Multiple dose levels allow for individualized treatment
• Strong clinical trial data from the SURMOUNT program
• Pre-filled pen device for easy administration

Cons:

• High cost without insurance (approximately $1,060 per month)
• Gastrointestinal side effects can be significant, particularly at higher doses
• No adolescent approval yet (as of early 2026)
• Newer medication with less long-term safety data compared to semaglutide
• No cardiovascular outcome trial completed for the weight loss indication (trials ongoing)
• Supply constraints have affected availability

Best for: Patients seeking maximum weight loss who can tolerate the medication's side effects. Particularly relevant for patients with type 2 diabetes (since tirzepatide has strong glucose-lowering effects) and those who have tried semaglutide without adequate results.

Liraglutide 3.0mg (Saxenda) - First-Generation Option

Saxenda is manufactured by Novo Nordisk and was approved by the FDA for chronic weight management in December 2014. It was the first GLP-1 receptor agonist approved specifically for obesity treatment. It contains liraglutide, the same active ingredient as Victoza (approved for type 2 diabetes at a lower dose).

How it works. Saxenda is a GLP-1 receptor agonist that works through the same general mechanism as semaglutide: reducing appetite, slowing gastric emptying, and improving insulin sensitivity. However, liraglutide has a shorter half-life than semaglutide, which means it requires daily injections rather than weekly injections.

Clinical trial evidence. The SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) trial program evaluated liraglutide 3.0mg for weight management.

In the SCALE Obesity and Prediabetes trial, participants lost an average of 8.0% of their body weight over 56 weeks, compared to 2.6% in the placebo group. About one in three participants lost 10% or more of their body weight. In participants with prediabetes, liraglutide also reduced the risk of progressing to type 2 diabetes by approximately 80% over three years.

Dosing schedule. Unlike the weekly GLP-1 medications, Saxenda is injected daily:

• Week 1: 0.6mg daily
• Week 2: 1.2mg daily
• Week 3: 1.8mg daily
• Week 4: 2.4mg daily
• Week 5 and beyond: 3.0mg daily (maintenance dose)

Pros:

• Longest track record of any GLP-1 weight loss medication (approved since 2014)
• Extensive long-term safety data
• Approved for adolescents ages 12 and older
• Demonstrated prediabetes prevention benefits
• Some patients tolerate the daily dosing and prefer the ability to adjust timing

Cons:

• Significantly lower average weight loss compared to Wegovy and Zepbound (8% vs 15-22%)
• Requires daily injections (less convenient than weekly options)
• High cost without insurance (approximately $1,300 per month)
• Many insurance plans now prefer Wegovy or Zepbound over Saxenda due to superior efficacy data
• Nausea and other GI side effects are still common

Best for: Patients who have specific contraindications to semaglutide or tirzepatide, those who prefer a daily medication with a long safety track record, or situations where Saxenda is the only covered option on an insurance formulary. Also sometimes used as a first-line option for patients who are hesitant about the newer medications.

Compounded Semaglutide - Access and Cost Advantages

Compounded semaglutide has become a significant part of the GLP-1 weight loss space, particularly for patients who cannot afford brand-name Wegovy or who face supply shortages. Understanding what compounded semaglutide is, how it differs from brand-name products, and what to look for in a compounding pharmacy is essential for making a safe and informed decision.

What is compounded semaglutide? Compounded semaglutide is a version of the semaglutide molecule prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk. Compounding pharmacies create customized medications by combining pharmaceutical-grade ingredients according to a prescription. This practice is regulated by state boards of pharmacy and, for larger operations, by the FDA under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Legal and regulatory status. The availability of compounded semaglutide is tied to drug shortage designations by the FDA. When a brand-name drug is on the FDA's drug shortage list, compounding pharmacies may legally produce compounded versions. The regulatory space around compounded GLP-1 medications has been evolving, and patients should stay informed about current regulations through their healthcare provider.

How it differs from brand-name Wegovy. Compounded semaglutide contains the same active molecule as Wegovy but may differ in several ways. The formulation may use semaglutide base or semaglutide sodium salt rather than the exact brand-name formulation. The injection device is typically a standard insulin syringe and multi-dose vial rather than the pre-filled Wegovy pen. The concentration may differ, requiring patients or providers to calculate and draw up the correct dose. Excipients (inactive ingredients) may vary from the brand-name product.

Cost. The primary advantage of compounded semaglutide is cost. While brand-name Wegovy costs approximately $1,350 per month without insurance, compounded semaglutide typically costs between $150 and $500 per month depending on the dose, pharmacy, and whether it is bundled with a telehealth consultation. This makes GLP-1 therapy accessible to patients who could not otherwise afford it.

Safety considerations. The safety of compounded semaglutide depends entirely on the quality and integrity of the compounding pharmacy. Patients should verify that the pharmacy is licensed in their state, registered with the appropriate state board of pharmacy, and ideally accredited by PCAB (Pharmacy Compounding Accreditation Board) or a similar organization. The pharmacy should use pharmaceutical-grade semaglutide sourced from FDA-registered suppliers, follow strict sterility and quality control procedures, and provide certificates of analysis for their products.

Patients should be cautious of compounded semaglutide sold at unusually low prices, offered without a valid prescription, shipped from overseas, or sold by entities that are not licensed pharmacies. These products may contain incorrect doses, contaminants, or may not contain semaglutide at all.

Best for: Patients who cannot afford brand-name Wegovy, those without insurance coverage for GLP-1 medications, patients facing brand-name supply shortages, and those who are comfortable with vial-and-syringe administration. Many online GLP-1 providers now offer compounded semaglutide programs that include telehealth consultations, prescriptions, and pharmacy fulfillment in a single package.

Learn more about semaglutide pricing in our GLP-1 Cost Without Insurance Guide.

Compounded Tirzepatide - Availability and Considerations

Similar to compounded semaglutide, compounded tirzepatide is produced by licensed compounding pharmacies as an alternative to brand-name Zepbound. The considerations are largely parallel but with some important differences.

Availability. Compounded tirzepatide availability is also tied to FDA drug shortage designations. Tirzepatide compounding has faced similar regulatory scrutiny as semaglutide compounding. Patients should work with their healthcare provider to understand current availability and regulatory status in their state.

Cost. Compounded tirzepatide typically costs $200 to $600 per month depending on the dose and pharmacy, compared to approximately $1,060 per month for brand-name Zepbound. The cost advantage is significant, though not quite as dramatic as with semaglutide since Zepbound's brand-name price is lower than Wegovy's.

Dosing considerations. Tirzepatide dosing in compounded form requires careful attention because the dose ranges are different from semaglutide. Compounded tirzepatide is typically supplied in multi-dose vials with a specific concentration, and patients must draw up the correct volume for their prescribed dose. Working with a knowledgeable provider who is experienced with tirzepatide dosing is important.

Dual mechanism benefits. Compounded tirzepatide retains the dual GLP-1/GIP mechanism of brand-name Zepbound when properly formulated with pharmaceutical-grade tirzepatide. This means patients can potentially access the superior weight loss results seen in clinical trials at a fraction of the brand-name cost.

Best for: Patients seeking the maximum weight loss potential of tirzepatide who cannot afford or access brand-name Zepbound. Particularly appealing for patients who have already tried semaglutide (brand-name or compounded) and want to try the dual-mechanism approach.

You can explore both semaglutide and tirzepatide options through FormBlends' vetted provider network.

Pipeline Medications (Orforglipron, Survodutide, Retatrutide)

The success of semaglutide and tirzepatide has sparked an enormous wave of research and development in the incretin-based medication space. Several promising medications are in late-stage clinical trials and may reach the market in the coming years. Understanding the pipeline helps set realistic expectations about what may be available soon.

Orforglipron (Eli Lilly). Orforglipron is a daily oral GLP-1 receptor agonist that would eliminate the need for injections entirely. In Phase 3 clinical trials, orforglipron has demonstrated weight loss results competitive with injectable semaglutide, with average weight loss of approximately 14-15% of body weight over 72 weeks. An oral pill form of GLP-1 therapy could dramatically improve patient compliance and acceptance, as many people are reluctant to self-inject. If approved, orforglipron could become a major option for patients who prefer oral medications. Eli Lilly has submitted regulatory applications and approval could come in 2026 or 2027.

Survodutide (Boehringer Ingelheim/Zealand Pharma). Survodutide is a dual GLP-1 and glucagon receptor agonist (note: glucagon, not GIP). The addition of glucagon receptor activation increases energy expenditure and promotes fat metabolism through a different pathway than tirzepatide. Phase 2 trial results showed average weight loss of approximately 18-19% over 46 weeks, with the highest dose groups showing even greater reductions. Survodutide is currently in Phase 3 trials, and its unique mechanism could offer benefits for patients who do not respond adequately to GLP-1-only or GLP-1/GIP medications.

Retatrutide (Eli Lilly). Retatrutide is a triple-mechanism drug that activates GLP-1, GIP, and glucagon receptors simultaneously. This "triple agonist" approach represents the forefront of incretin-based weight loss therapy. In Phase 2 trials, retatrutide produced remarkable results, with average weight loss of approximately 24% of body weight at the highest dose over 48 weeks. Some participants lost more than 30% of their starting weight. Phase 3 trials are underway. If these results hold up in larger studies, retatrutide could set a new benchmark for pharmaceutical weight loss. However, it is still several years from potential FDA approval.

CagriSema (Novo Nordisk). CagriSema combines semaglutide with cagrilintide, an amylin receptor agonist. Amylin is another hormone involved in appetite regulation and gastric emptying. This combination targets multiple appetite pathways simultaneously. Phase 3 trial results have shown weight loss results competitive with or exceeding tirzepatide, with some analyses suggesting average weight loss above 20%. Novo Nordisk is pursuing regulatory approval, and CagriSema could become available in the coming years.

These pipeline medications represent the future of GLP-1 and incretin-based weight loss therapy. However, it is important to make treatment decisions based on medications that are currently available and proven, rather than waiting for something that may still be years away from reaching patients.

How to Choose Between GLP-1 Medications

With multiple GLP-1 options available, choosing the right medication can feel overwhelming. The truth is that no single GLP-1 medication is universally "best." The right choice depends on your specific health profile, priorities, budget, and how your body responds to treatment. This section provides a structured framework for comparing your options and making an informed decision with your healthcare provider.

Efficacy Comparison (Percent Weight Loss by Medication)

Weight loss efficacy is often the first factor patients consider, and the differences between medications are meaningful.

Clinical trial data provides the most reliable comparison, though trial results represent averages across large populations. Your individual results may be higher or lower than these averages.

Tirzepatide (Zepbound) at the maximum 15mg dose has demonstrated the highest average weight loss in clinical trials: 22.5% of body weight over 72 weeks in the SURMOUNT-1 trial. At the 10mg dose, average weight loss was 19.5%, and at the 5mg dose, average weight loss was 15.0%.

Semaglutide 2.4mg (Wegovy) produced average weight loss of 14.9% over 68 weeks in the STEP 1 trial. When combined with intensive behavioral therapy in STEP 3, average weight loss reached 16.0%.

Liraglutide 3.0mg (Saxenda) produced average weight loss of 8.0% over 56 weeks in the SCALE trial. This is substantially lower than both Wegovy and Zepbound.

These numbers represent group averages. Within each trial, some participants lost significantly more weight while others lost less. The top responders in the SURMOUNT-1 trial lost 30% or more of their body weight, while some participants in all trials lost less than 5%. Response to GLP-1 medications is influenced by genetics, adherence, lifestyle factors, and other variables that are not fully understood.

Compounded semaglutide and compounded tirzepatide should theoretically produce similar results to their brand-name counterparts when properly formulated and dosed, though they have not been studied in the same rigorous clinical trial format.

Side Effect Profiles

All GLP-1 medications share a similar core side effect profile, dominated by gastrointestinal symptoms. However, there are some differences in frequency and severity between medications.

Nausea is the most commonly reported side effect across all GLP-1 medications. It affects approximately 44% of patients on semaglutide 2.4mg, 33% of patients on tirzepatide (15mg dose), and 40% of patients on liraglutide 3.0mg. Nausea is most common during the dose titration period and typically improves as the body adjusts.

Diarrhea affects approximately 30% of patients on semaglutide 2.4mg, 25% on tirzepatide, and 21% on liraglutide 3.0mg.

Constipation affects approximately 24% of patients on semaglutide 2.4mg, 26% on tirzepatide (a somewhat higher rate that may be related to the GIP component), and 19% on liraglutide 3.0mg.

Vomiting affects approximately 24% of patients on semaglutide 2.4mg, 12% on tirzepatide, and 16% on liraglutide 3.0mg. Tirzepatide has a notably lower vomiting rate than semaglutide in head-to-head analyses.

Injection site reactions are generally mild and uncommon with all three medications. Some patients experience redness, swelling, or itching at the injection site that typically resolves within a day.

Serious but rare side effects that have been reported with GLP-1 medications include pancreatitis (inflammation of the pancreas), gallbladder problems including gallstones, and potential thyroid effects (based on animal studies, leading to the boxed warning about medullary thyroid carcinoma). These serious effects are uncommon but require monitoring.

Most gastrointestinal side effects are manageable and tend to improve after the first 4 to 8 weeks on a stable dose. Eating smaller meals, avoiding high-fat foods, staying hydrated, and following the recommended dose titration schedule are the most effective strategies for minimizing side effects.

Cost and Insurance Coverage

Cost is often the deciding factor in medication choice, particularly for patients without comprehensive insurance coverage. The price differences between options are substantial.

Brand-name Wegovy costs approximately $1,350 per month without insurance. Brand-name Zepbound costs approximately $1,060 per month. Brand-name Saxenda costs approximately $1,300 per month. These prices can vary by pharmacy and region.

Compounded semaglutide ranges from $150 to $500 per month. Compounded tirzepatide ranges from $200 to $600 per month. These prices vary widely based on the pharmacy, dose, and whether the cost includes a provider consultation.

Insurance coverage is improving but remains inconsistent. Approximately 40-50% of commercial insurance plans now cover at least one GLP-1 medication for weight management. Medicare Part D coverage for anti-obesity medications has expanded following the TREAT Act. Medicaid coverage varies significantly by state. We cover insurance in detail in a later section of this guide.

For patients paying out of pocket, the manufacturer savings programs can help. Novo Nordisk and Eli Lilly both offer savings cards for commercially insured patients that can reduce out-of-pocket costs significantly. However, these programs do not apply to government insurance (Medicare, Medicaid, Tricare) or to patients without any insurance coverage.

For a complete breakdown of pricing, see our GLP-1 Cost Without Insurance Guide.

Injection Frequency and Convenience

Injection frequency is a practical consideration that affects daily life and medication adherence.

Weekly injections (Wegovy and Zepbound): Both semaglutide 2.4mg and tirzepatide are injected once per week. Patients choose a consistent day of the week and inject at approximately the same time each week. The injection can be given at any time of day, with or without food. Weekly dosing is highly convenient and is associated with high adherence rates in clinical trials.

Daily injections (Saxenda): Liraglutide 3.0mg is injected once daily. While the injection itself takes only a few seconds, the daily requirement adds up over time. Some patients find daily injections manageable and even prefer the routine, while others find it burdensome compared to weekly alternatives.

Compounded medications: Compounded semaglutide is typically injected weekly, and compounded tirzepatide is typically injected weekly, mirroring the brand-name schedules. However, some compounding formulations may use different concentrations that require slightly different injection volumes.

For patients who are needle-averse, the upcoming oral GLP-1 options (like orforglipron) may eventually provide an injection-free alternative. In the meantime, the needles used for GLP-1 injections are very small (30-32 gauge), and most patients report that injections are far less painful than they expected.

Special Considerations (Diabetes, Heart Disease, PCOS)

Certain medical conditions may make one GLP-1 medication a better fit than others.

Type 2 diabetes. If you have both obesity and type 2 diabetes, tirzepatide may be particularly advantageous. The SURPASS clinical trial program showed that tirzepatide produced HbA1c reductions of 2.0-2.4%, which is among the best of any diabetes medication. Semaglutide is also highly effective for glucose control. In some cases, your provider may prescribe the diabetes-specific versions (Mounjaro or Ozempic) rather than the weight management versions (Zepbound or Wegovy) to optimize insurance coverage for the diabetes indication.

Cardiovascular disease. If you have established cardiovascular disease or significant cardiovascular risk factors, semaglutide (Wegovy) has the strongest evidence base. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events. This is currently the only GLP-1 weight loss medication with a proven cardiovascular outcome benefit. Tirzepatide cardiovascular outcome trials are ongoing but not yet completed.

PCOS. Women with polycystic ovary syndrome may benefit from either semaglutide or tirzepatide. Both medications improve insulin sensitivity, which is a core driver of PCOS symptoms. Some emerging evidence suggests that tirzepatide's dual mechanism may provide particular benefits for insulin resistance and hormonal balance in PCOS, but more research is needed. Any GLP-1 medication used in women of reproductive age requires discussion about contraception, as these medications should be discontinued at least two months before planned pregnancy.

Non-alcoholic fatty liver disease. Semaglutide has the most data specifically showing liver fat reduction and improvement in liver inflammation markers. The Phase 2 trial of semaglutide in NASH (now called MASH) showed that 59% of patients on semaglutide achieved resolution of their liver inflammation, compared to 17% on placebo.

Kidney disease. The FLOW trial demonstrated that semaglutide significantly slowed the progression of chronic kidney disease in patients with type 2 diabetes and CKD. For patients with obesity and kidney concerns, semaglutide may offer specific renal benefits. Dose adjustments may be needed for patients with severe kidney impairment.

Decision Framework for Patients

The following framework can help guide your medication discussion with your healthcare provider. Keep in mind that this is a starting point, not a definitive recommendation. Your provider will consider factors specific to your medical history that may not be captured here.

The most important step is having an open conversation with your healthcare provider about your goals, preferences, and constraints. No decision framework can replace personalized medical advice.

The Consultation Process - From First Appointment to First Dose

Understanding the consultation process removes uncertainty and helps you arrive prepared. Whether you see a provider in person or through a telehealth platform, the path from initial consultation to your first dose follows a similar trajectory. Here is a detailed walkthrough of each step.

What to Expect at a Telehealth Consultation

Telehealth consultations for GLP-1 medications have become the most common pathway for many patients, offering convenience, shorter wait times, and often more competitive pricing compared to traditional office visits. Here is what a typical telehealth consultation looks like.

Pre-consultation intake. Before your video or phone appointment, you will complete a detailed health questionnaire. This typically covers your current weight, height, and BMI; your medical history including current diagnoses and past surgeries; a list of current medications and supplements; your weight loss history including previous diets, programs, and medications you have tried; family medical history, particularly regarding thyroid conditions, diabetes, and cardiovascular disease; your goals and expectations for treatment; and any known allergies to medications.

Some platforms also ask you to upload recent lab work if available. While not always required for the initial consultation, having recent labs (within the past 6 to 12 months) can simplify the process. Key labs include fasting glucose or HbA1c, lipid panel, thyroid function (TSH), kidney function (creatinine, eGFR), and liver function (ALT, AST).

The consultation itself. A licensed healthcare provider (physician, nurse practitioner, or physician assistant, depending on the platform and state regulations) will review your intake information and discuss your health history in more detail. They will assess whether you meet eligibility criteria, discuss medication options, explain potential side effects and risks, and answer your questions. The consultation typically lasts 15 to 30 minutes.

Be honest and thorough during this consultation. Withholding information about your medical history, current medications, or previous health issues can lead to an inappropriate prescription that puts your health at risk. If you have a complex medical history, mention everything and let the provider determine what is relevant.

After the consultation. If you are approved for treatment, the provider will write a prescription and send it to the appropriate pharmacy. Some telehealth platforms have partnerships with specific compounding pharmacies or retail pharmacies and handle the fulfillment process directly. Others send prescriptions to the pharmacy of your choice.

For a comparison of the top telehealth platforms offering GLP-1 prescriptions, see our Best Online GLP-1 Providers guide.

Required Health Information and Labs

Different providers and platforms have different requirements, but the following represents a comprehensive list of what you may need.

Always required:

• Current height and weight (for BMI calculation)
• Complete medical history
• Current medication list
• Allergy information
• Pregnancy status (for women of childbearing age)

Commonly required:

• Fasting glucose and/or HbA1c (to screen for diabetes/prediabetes)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Thyroid function (TSH, sometimes free T4)
• Basic metabolic panel (kidney function, electrolytes)
• Blood pressure reading (can often be taken at a pharmacy or at home)

Sometimes required:

• Liver function tests (ALT, AST)
• Fasting insulin level
• Complete blood count (CBC)
• Vitamin D level
• Vitamin B12 level
• Inflammatory markers (CRP, ESR)

If you do not have recent lab work, many telehealth platforms can order labs for you through partner laboratories like Quest Diagnostics or Labcorp. Some platforms include lab work in their consultation fee, while others charge separately. You can also ask your primary care provider to order labs before your GLP-1 consultation.

How Prescribers Choose Your Medication

When your prescriber evaluates you for GLP-1 therapy, they consider multiple factors to recommend the most appropriate medication for your situation.

Medical history and comorbidities. If you have type 2 diabetes, your provider may favor tirzepatide for its superior glucose-lowering effects, or may prescribe the diabetes-specific version (Mounjaro or Ozempic) for better insurance coverage. If you have cardiovascular disease, semaglutide is likely preferred due to the SELECT trial data. If you have PCOS or NAFLD, either semaglutide or tirzepatide may be recommended based on available evidence.

Insurance coverage. Your insurance formulary significantly influences the recommendation. If your plan covers Wegovy but not Zepbound, that becomes the practical choice. If neither brand-name medication is covered, your provider may recommend compounded options or help you navigate the prior authorization process. They will check your specific plan to determine what is realistic before writing a prescription.

Previous treatment history. If you have previously tried a GLP-1 medication with inadequate results, your provider will likely recommend a different option. For example, a patient who did not lose enough weight on semaglutide might be switched to tirzepatide. A patient who could not tolerate semaglutide's side effects might try tirzepatide (which has a lower vomiting rate) or liraglutide (which some patients tolerate better due to its shorter half-life).

Patient preferences. Your preferences matter. If you strongly prefer weekly injections over daily ones, Saxenda is off the table. If cost is your primary concern and you do not have insurance coverage, compounded options become the likely recommendation. If you want the medication with the most clinical data, semaglutide has the longest and most extensive trial program.

Contraindications. Certain medical conditions may rule out specific medications. Your provider will cross-reference your health history with the contraindication profiles of each medication to ensure safety.

Insurance Pre-Authorization Process

If you plan to use insurance to cover your GLP-1 medication, prior authorization is almost always required. This is a process where your insurance company reviews your medical information to determine whether they will cover the medication before it is dispensed.

What triggers prior authorization. Nearly all insurance plans require prior authorization for GLP-1 weight loss medications because these are expensive specialty drugs. Your provider submits documentation proving that you meet the plan's criteria for coverage, which typically includes BMI documentation, evidence of weight-related comorbidities, and documentation that lifestyle interventions (diet and exercise) have been attempted but were insufficient.

Timeline. Prior authorization decisions typically take 5 to 15 business days. Some plans offer expedited review in urgent cases, which can return a decision within 24 to 72 hours. Your provider's office or the telehealth platform will handle the submission and follow up with the insurance company. You should ask about the expected timeline so you can plan accordingly.

Common reasons for denial. Prior authorization requests are denied when BMI does not meet the plan's threshold (some plans require BMI of 30+ even for the 27+ with comorbidity pathway), when there is insufficient documentation of weight-related comorbidities, when the plan requires proof that other weight loss interventions were tried first (sometimes a specific number of months of documented attempts), when the requested medication is not on the plan's formulary, or when required lab work or clinical documentation is missing.

If your prior authorization is denied, you have the right to appeal. We cover the appeal process in the insurance section later in this guide.

Pharmacy Fulfillment (Brand vs Compounding)

Brand-name pharmacy fulfillment. Brand-name GLP-1 medications (Wegovy, Zepbound, Saxenda) are dispensed through retail pharmacies (CVS, Walgreens, etc.) or specialty pharmacies. Once your prescription and any required prior authorization are in place, the pharmacy processes the order and either prepares it for pickup or ships it to your address. Brand-name medications come in pre-filled pen devices that are ready to use.

Compounded pharmacy fulfillment. Compounded GLP-1 medications are prepared by licensed compounding pharmacies and typically shipped directly to your address. The compounding pharmacy receives the prescription from your provider, prepares your medication to the specified dose and concentration, and ships it in temperature-controlled packaging. Compounded medications typically come in multi-dose vials with separate syringes for injection.

Shipping for both brand-name and compounded medications usually takes 3 to 7 business days. Medications that require refrigeration are shipped with cold packs to maintain proper temperature during transit. You should be available to receive the package and refrigerate it promptly upon arrival.

Timeline from Consultation to First Injection

The total time from scheduling your consultation to administering your first injection varies based on several factors.

Fastest path (compounded, no insurance): If you are paying out of pocket and using a telehealth platform with an integrated compounding pharmacy, the process can be remarkably fast. Consultation within 1 to 3 days of scheduling, prescription written the same day, pharmacy fulfillment and shipping in 3 to 7 days. Total time: approximately 5 to 10 days from scheduling to first injection.

Moderate path (brand-name with insurance): If you are using insurance for a brand-name medication, the process takes longer due to prior authorization. Consultation within 1 to 7 days of scheduling, prior authorization submission the same day or next business day, prior authorization decision in 5 to 15 business days, pharmacy fulfillment and pickup/shipping in 1 to 5 days. Total time: approximately 2 to 4 weeks from scheduling to first injection.

Longest path (brand-name with insurance denial and appeal): If your initial prior authorization is denied and you need to appeal, add an additional 2 to 6 weeks for the appeal process. Total time: approximately 6 to 10 weeks from scheduling to first injection.

If speed is important to you and you can afford the out-of-pocket cost, starting with compounded medication while simultaneously pursuing insurance coverage for a brand-name option is a common strategy. This allows you to begin treatment quickly while working through the insurance process in parallel.

Insurance Coverage for GLP-1 in 2026

Insurance coverage for GLP-1 weight loss medications has been one of the biggest barriers to access since these drugs first became available. The space has improved significantly in recent years, but coverage remains inconsistent across different plan types, states, and employers. This section provides a detailed overview of the current insurance environment and practical strategies for maximizing your coverage.

For our full deep-dive on this topic, see the GLP-1 Insurance Coverage Complete Guide.

Commercial Insurance (What Has Changed)

Commercial insurance (employer-sponsored plans and individual marketplace plans) represents the largest category of health coverage in the United States. Coverage of GLP-1 weight loss medications through commercial insurance has expanded meaningfully over the past two years.

As of early 2026, approximately 40 to 50 percent of commercial insurance plans cover at least one GLP-1 medication for chronic weight management. This is a significant increase from approximately 25 to 30 percent in 2024. The expansion has been driven by several factors: growing employer recognition that treating obesity reduces downstream healthcare costs, increasing evidence of cardiovascular and metabolic benefits beyond weight loss, competitive pressure among insurers as more plans add coverage, and state-level legislation in some states mandating coverage parity for obesity treatments.

However, significant variation remains. Large employer-sponsored plans are more likely to cover GLP-1 medications than small-group or individual marketplace plans. Plans that cover weight management medications typically require prior authorization and may limit coverage to specific medications (often Wegovy or Zepbound, but not always both). Some plans impose step therapy requirements, meaning you must try and fail a less expensive medication (like Saxenda or even non-GLP-1 weight loss drugs) before they will cover Wegovy or Zepbound.

Out-of-pocket costs for commercially insured patients who have coverage vary widely. Some patients pay as little as $25 to $50 per month with manufacturer savings cards combined with their insurance copay. Others face copays of $200 to $500 per month depending on their plan's formulary tier placement and cost-sharing structure.

Medicare Part D (New Obesity Medication Coverage)

Medicare coverage of anti-obesity medications has undergone a historic shift. For decades, Medicare Part D explicitly excluded coverage for drugs prescribed for weight loss or cosmetic purposes. This changed with the passage of the Treat and Reduce Obesity Act (TREAT Act), which removed the Medicare exclusion for anti-obesity medications.

As of 2026, Medicare Part D plans can now cover FDA-approved anti-obesity medications including Wegovy, Zepbound, and Saxenda. This is a major development for the millions of Medicare beneficiaries living with obesity. However, coverage implementation varies by plan. Not all Part D plans have added GLP-1 weight loss medications to their formularies yet, and those that have may place them on higher tiers with greater cost-sharing. Prior authorization is standard. Plans may also impose quantity limits or require documentation of prior weight loss attempts.

Medicare beneficiaries should review their Part D plan's formulary during the annual enrollment period and consider switching plans if their current plan does not cover the GLP-1 medication they need. Medicare.gov's plan finder tool allows beneficiaries to search for plans that cover specific medications in their area.

Medicaid Coverage by State

Medicaid coverage for GLP-1 weight loss medications is the most inconsistent of all insurance categories, varying dramatically from state to state. Some states have expanded Medicaid coverage to include anti-obesity medications, while others continue to exclude them.

States that have moved toward covering GLP-1 medications for weight management include several larger states with significant Medicaid populations. However, even in states that offer coverage, strict prior authorization requirements, limited formularies, and mandatory step therapy protocols are common.

Medicaid beneficiaries should contact their state Medicaid office or managed care organization to ask about current coverage for specific GLP-1 medications. Given the rapidly evolving space, information from even six months ago may be outdated. If your state Medicaid program does not cover GLP-1 weight loss medications, compounded alternatives paid out of pocket may be the most accessible option.

Prior Authorization - How to Get Approved

Prior authorization is the most common hurdle between a prescription and getting your medication. Here are strategies to maximize your chances of approval on the first attempt.

Provide comprehensive documentation. The most common reason for denial is incomplete documentation. Ensure your submission includes current BMI calculation with documented height and weight, a complete list of weight-related comorbidities with supporting lab work or diagnostic records, documentation of previous weight loss attempts (ideally including dates and duration of diet and exercise programs or previous medications), current lab results supporting the medical necessity of treatment, and a clinical note from your prescriber explaining why GLP-1 medication is medically necessary for your specific situation.

Know your plan's specific criteria. Before submitting, call your insurance company or review your plan documents to understand exactly what they require. Some plans have specific BMI thresholds, mandatory time periods of documented lifestyle interventions, or requirements for specific types of prior weight loss attempts. Knowing these requirements upfront allows you to tailor the submission accordingly.

Use the right diagnosis codes. Your provider should use the most specific and medically supportive diagnosis codes. The primary diagnosis should be obesity (ICD-10 code E66.01 for morbid obesity or E66.09 for other obesity). Additional codes for comorbidities (type 2 diabetes, hypertension, dyslipidemia, etc.) should also be included. Using appropriate diagnosis codes signals medical necessity to the insurance reviewer.

Include clinical guidelines references. Referencing established clinical guidelines in the prior authorization letter can strengthen the case. The American Association of Clinical Endocrinology (AACE), the American Heart Association (AHA), and the Obesity Medicine Association all publish guidelines supporting pharmacotherapy for patients who meet BMI criteria.

Appeal Process If Denied

If your prior authorization is denied, do not give up. Approximately 40 to 60 percent of prior authorization denials for GLP-1 weight loss medications are overturned on appeal. The appeal process typically works as follows.

First-level appeal (internal review). You or your provider submit a written appeal to the insurance company, often with additional supporting documentation that addresses the specific reason for the denial. Include a detailed letter from your prescriber explaining the medical necessity, any additional lab work or documentation that was missing from the initial submission, references to clinical guidelines supporting GLP-1 therapy for your condition, and information about why alternative treatments are insufficient or inappropriate for your situation. This review typically takes 15 to 30 days.

Second-level appeal (external review). If the internal appeal is denied, most states allow you to request an external review by an independent third party. This independent reviewer examines your case without the bias of the insurance company's cost considerations. External reviews frequently reverse internal denials, particularly when strong medical documentation is provided.

Peer-to-peer review. Some insurance companies offer peer-to-peer reviews where your prescribing provider speaks directly with the insurance company's medical director. This can be very effective, as it allows your provider to advocate for you in real-time and address specific objections.

When Compounding Is the Better Financial Option

For many patients, compounded GLP-1 medications are the most practical and affordable path to treatment. Compounding is likely the better financial option when your insurance does not cover any GLP-1 weight loss medication, when your insurance copay for brand-name medication is higher than the compounded price, when your prior authorization has been denied and the appeal process is lengthy, when you are in the Medicare coverage gap (donut hole) and facing high out-of-pocket costs, or when brand-name supply shortages make the medication unavailable through your pharmacy.

At a cost of $150 to $500 per month for compounded semaglutide (versus $1,350 per month for brand-name Wegovy), the annual savings can range from $10,000 to $14,000. For many patients, this cost difference makes the difference between being able to afford treatment and going without.

Browse GLP-1 options on FormBlends to compare compounded medication programs that include provider consultations and pharmacy fulfillment.

What to Expect Month by Month on GLP-1

Setting realistic expectations is one of the most important factors in a successful GLP-1 weight loss process. Knowing what typically happens at each stage helps you stay motivated during slower periods and avoid unnecessary concern about normal fluctuations. The following timeline is based on aggregated clinical trial data and real-world prescribing experience, but your individual experience may differ.

Month 1-2 (Titration, Adjustment, Initial Weight Loss)

The first two months are the titration phase, where your dose is gradually increased from the starting level toward the target maintenance dose. This period is about letting your body adjust to the medication while beginning to experience its effects.

What happens biologically. During the first few weeks, the GLP-1 medication begins binding to receptors in your brain and gut. Appetite suppression starts relatively quickly, often within the first week. You may notice that you feel full faster during meals, that you think about food less often between meals, and that cravings for high-calorie foods diminish. Gastric emptying slows, meaning food stays in your stomach longer and you feel satisfied for a longer time after eating.

Expected weight loss. Most patients lose between 2% and 5% of their body weight during the first two months. For a 250-pound person, that translates to approximately 5 to 12.5 pounds. Some patients lose more, particularly if they are also making significant dietary changes. Others may lose less, especially if they are on the lowest titration doses.

Common experiences. Reduced appetite is the most noticeable change for most people. Many patients describe it as a "quieting" of food noise, meaning the constant background thoughts about food that many people with obesity experience become much less frequent and intense. Nausea is common, particularly in the first 1 to 2 weeks after each dose increase. It is usually mild to moderate and improves as your body adjusts. Some patients experience fatigue, headaches, or mild dizziness as their caloric intake decreases. Constipation or diarrhea may occur as your digestive system adjusts to slower gastric emptying.

Tips for this phase. Eat smaller, more frequent meals rather than large portions. Stay well hydrated, aiming for at least 64 ounces of water daily. If nausea is bothersome, try eating bland foods and avoiding greasy or spicy meals. Start building protein-forward eating habits now, as adequate protein intake becomes increasingly important as weight loss progresses. Begin or continue a regular exercise routine, even if it is just walking. Do not get discouraged if weight loss seems slow. The medication is still at a low dose, and the foundation is being set.

Month 3-6 (Acceleration, Maximum Dose, Plateau Strategies)

Months 3 through 6 are typically the most dramatic phase of weight loss. By this point, most patients have titrated to their maintenance dose (or close to it), and the medication's full effects are in play.

Expected weight loss. Cumulative weight loss by month 6 typically reaches 8% to 15% of starting body weight for patients on semaglutide or tirzepatide. For our 250-pound example, that is 20 to 37.5 pounds. The rate of loss may accelerate noticeably once you reach the higher doses. Many patients report that months 3 and 4 are when they see the most rapid changes on the scale.

Common experiences. Appetite suppression is typically strongest during this period. Some patients report having to remind themselves to eat, which is important because skipping meals entirely can lead to muscle loss and nutritional deficiencies. Clothing sizes change noticeably. Energy levels often improve as excess weight decreases. Sleep quality may improve, particularly for patients with sleep apnea. Blood sugar, blood pressure, and cholesterol readings often begin to improve significantly. Some patients experience temporary hair thinning (telogen effluvium) due to rapid weight loss. This is not caused by the medication itself but by the caloric deficit and rapid weight change.

Plateau strategies. Some patients experience a weight loss plateau during this period, where the scale stalls for 2 to 4 weeks despite consistent medication use and adherence to dietary changes. Plateaus are normal and do not mean the medication has stopped working. Strategies for breaking through a plateau include reassessing portion sizes (even with reduced appetite, portions can creep up over time), increasing protein intake to preserve muscle mass and maintain metabolic rate, adding or intensifying resistance training, improving sleep quality, managing stress levels, and talking to your provider about dose optimization if you have not yet reached the maximum dose.

Month 6-12 (Maintenance, Lifestyle Optimization)

The second half of the first year is when weight loss typically begins to decelerate and the focus shifts toward maintaining and optimizing results. This is a natural progression, not a sign of failure.

Expected weight loss. By month 12, cumulative weight loss typically reaches 12% to 22% of starting body weight, depending on the medication and individual response. The rate of weekly weight loss slows compared to the acceleration phase, which is expected. Some patients continue to lose weight steadily through month 12, while others reach a relatively stable weight between months 8 and 10.

Common experiences. Weight loss rate slows, which can be psychologically challenging for patients who became accustomed to rapid progress. This is a good time to shift focus from the scale to other health markers (lab improvements, fitness gains, reduced medication needs for other conditions, improved mobility and quality of life). Body composition changes become more apparent. Even if the scale is moving slowly, patients often notice continued changes in body shape, muscle definition, and how clothing fits. Many patients are able to reduce or discontinue medications for blood pressure, cholesterol, or blood sugar during this period, under their provider's guidance. Energy and mood improvements are consistently reported by patients who have maintained their weight loss through this period.

Lifestyle optimization. This is the ideal time to solidify the lifestyle habits that will support long-term weight maintenance. Focus on establishing a consistent exercise routine that includes both cardiovascular activity and resistance training, developing sustainable eating patterns centered on protein and whole foods, building stress management and sleep hygiene practices, and working with your provider to set long-term treatment goals.

Beyond 12 Months (Long-Term Treatment Decisions)

After 12 months on GLP-1 medication, you and your provider will make important decisions about the long-term treatment plan. The current medical understanding of obesity as a chronic disease means that many patients benefit from continued treatment.

Continuing medication. Many obesity medicine specialists now recommend long-term GLP-1 therapy for patients who have responded well, similar to how blood pressure or cholesterol medications are prescribed on an ongoing basis. Clinical trial extension studies consistently show that patients who continue GLP-1 medication maintain their weight loss, while those who discontinue tend to regain a significant portion of the lost weight.

Dose optimization. Some patients are able to reduce their dose after reaching their weight loss goal while still maintaining their results. For example, a patient who reached their goal on semaglutide 2.4mg might maintain their weight on 1.7mg or even 1.0mg. This is not possible for everyone but is worth discussing with your provider. A lower maintenance dose can reduce side effects and costs.

Discontinuation considerations. If you and your provider decide to discontinue GLP-1 medication, what to expect. The STEP 1 extension trial showed that participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide. The SURMOUNT-4 trial showed similar patterns with tirzepatide. Weight regain is not a personal failure. It reflects the biological reality that the hormonal and neurological mechanisms driving obesity return when the medication is removed. If you do discontinue, maintain the lifestyle habits you built during treatment and monitor your weight closely. If regain begins, early re-initiation of medication can prevent a return to your starting weight.

Switching medications. Some patients transition from one GLP-1 medication to another based on changing circumstances, insurance coverage, or response patterns. For example, a patient who started on compounded semaglutide might switch to brand-name Wegovy if insurance coverage becomes available, or a patient on semaglutide who plateaus might switch to tirzepatide for its higher average weight loss potential.

Maximizing Your Results - What the Data Shows

GLP-1 medications are powerful tools, but they produce the best results when combined with specific lifestyle strategies. The patients who achieve the greatest and most sustainable weight loss are those who use the medication as part of a comprehensive approach that includes nutrition, exercise, sleep, and behavioral changes. Here is what the evidence shows about each factor.

Protein Intake (60-100g Per Day Preserves Muscle)

Protein intake is arguably the single most important dietary factor during GLP-1 weight loss therapy. When you lose weight rapidly, your body breaks down both fat and muscle. Losing too much muscle mass reduces your metabolic rate, decreases functional strength, and can negatively affect long-term health outcomes.

Research consistently shows that adequate protein intake during weight loss helps preserve lean muscle mass, maintain metabolic rate, improve satiety (complementing the appetite-suppressing effects of GLP-1 medications), and support recovery from exercise.

The general recommendation for protein intake during active weight loss is 0.7 to 1.0 grams of protein per pound of ideal body weight per day. For most patients on GLP-1 medications, this translates to approximately 60 to 100 grams of protein daily. Some providers recommend even higher protein targets of 80 to 120 grams daily, especially for patients who are actively resistance training.

Because GLP-1 medications significantly reduce appetite, many patients find it challenging to eat enough food in general and protein specifically. This makes it important to prioritize protein at every meal and snack. Practical protein-rich food options include Greek yogurt (15-20g per cup), chicken breast (30g per 4-ounce serving), eggs (6g per egg), cottage cheese (14g per half cup), fish (20-25g per 4-ounce serving), lentils (18g per cup cooked), whey or plant protein shakes (20-30g per serving), and lean ground turkey (22g per 4-ounce serving).

Protein shakes and smoothies can be particularly helpful for patients who struggle to eat solid food due to reduced appetite or nausea. A protein shake with 25 to 30 grams of protein provides significant nutritional value in a form that many patients find easy to tolerate.

Resistance Training (Critical for Body Composition)

If there is one lifestyle recommendation that should be considered non-negotiable during GLP-1 therapy, it is resistance training. While any physical activity is beneficial, resistance training (also called strength training or weight training) is specifically important for preserving muscle mass during rapid weight loss.

Studies of weight loss through any method (diet, medication, or surgery) consistently show that approximately 25% to 40% of weight lost is lean mass (primarily muscle) rather than fat. Resistance training can significantly reduce this proportion, helping ensure that a larger percentage of weight lost comes from fat stores.

You do not need to become a powerlifter or join an expensive gym to benefit from resistance training. Effective programs can be performed at home with minimal equipment. The key principles include training each major muscle group at least twice per week, using progressive overload (gradually increasing weight, reps, or sets over time), including compound movements (squats, deadlifts, rows, presses) that work multiple muscle groups simultaneously, starting with a manageable program and building gradually (especially if you are new to strength training), and allowing adequate rest between training sessions for each muscle group.

If you are new to resistance training, consider working with a certified personal trainer for a few sessions to learn proper form and develop a safe, effective program. Many patients find that as they lose weight, their ability and desire to exercise increases, creating a positive feedback loop.

Sleep Quality

Sleep is an often-overlooked factor in weight loss success. Research shows that poor sleep quality and insufficient sleep duration are associated with reduced weight loss even when dietary and medication adherence are strong.

Poor sleep affects weight loss through several mechanisms. It increases levels of ghrelin (the hunger hormone) and decreases levels of leptin (the satiety hormone), partially counteracting the appetite-suppressing effects of GLP-1 medications. It reduces insulin sensitivity, making it harder for your body to process glucose effectively. It impairs recovery from exercise, reducing the benefits of physical activity. It affects willpower and decision-making, making it harder to stick to nutritional goals. It increases cortisol production, which promotes fat storage, particularly in the abdominal area.

Aim for 7 to 9 hours of quality sleep per night. Strategies for improving sleep include maintaining a consistent sleep and wake schedule (even on weekends), keeping the bedroom dark, cool, and quiet, avoiding screens for 30 to 60 minutes before bed, limiting caffeine intake to the morning hours, and addressing untreated sleep apnea (which may improve as you lose weight on GLP-1 therapy).

Hydration

Adequate hydration is particularly important during GLP-1 therapy for several reasons. First, GLP-1 medications slow gastric emptying, and adequate fluid intake helps maintain healthy digestion and prevent constipation (one of the most common side effects). Second, dehydration can worsen nausea, which is already a common side effect during dose titration. Third, water is essential for the metabolic processes involved in fat breakdown and elimination. Fourth, thirst is sometimes confused with hunger, and staying well hydrated helps you accurately interpret your body's signals.

The general recommendation is at least 64 ounces (8 cups) of water daily, though many providers recommend 80 to 100 ounces during active weight loss. Increase intake if you exercise, live in a hot climate, or experience diarrhea (another common GLP-1 side effect). Water is the ideal hydration source. Herbal teas, sparkling water, and water flavored with fruit or cucumber are also good options. Limit sugary drinks and high-calorie beverages that add calories without nutritional value.

Behavioral Changes That Stick

GLP-1 medications provide a biological foundation for weight loss by reducing appetite and cravings. But lasting success also requires developing behavioral patterns that you can maintain long-term, whether or not you continue medication.

Mindful eating. GLP-1 medications reduce the intensity of hunger and cravings, creating an opportunity to develop a healthier relationship with food. Practice eating slowly, paying attention to satiety signals, and stopping when comfortably satisfied rather than overly full. Many patients report that GLP-1 therapy gives them the "space" to be more intentional about food choices for the first time.

Meal planning and preparation. When appetite is reduced, it is easy to skip meals or make poor food choices simply because nothing sounds appealing. Planning and preparing protein-rich meals in advance ensures that when you do eat, you are meeting your nutritional needs. Batch cooking on weekends, keeping pre-portioned protein snacks available, and having a rotation of simple, protein-forward recipes can make a significant difference.

Stress management. Emotional eating is a common driver of weight gain, and while GLP-1 medications reduce the biological drive to eat, they may not fully eliminate the psychological habit of turning to food during stressful times. Developing alternative coping strategies such as walking, journaling, meditation, social connection, or professional counseling can help break the emotional eating cycle.

Social support. Weight loss experiences are significantly more successful with social support. This might come from a partner or family member, a friend who is also on a health process, an online community of other GLP-1 patients, or a support group offered by your provider or telehealth platform. Having people who understand what you are going through provides accountability, encouragement, and practical advice.

Regular monitoring. Tracking your progress helps maintain motivation and catch potential problems early. This does not have to mean obsessing over the scale. Useful monitoring practices include weekly weigh-ins at a consistent time, monthly body measurements (waist, hips, chest), regular progress photos, tracking fitness improvements (steps walked, weight lifted, endurance milestones), and periodic lab work to monitor health marker improvements.

Who Should NOT Take GLP-1 Medications

While GLP-1 medications are safe and effective for many people, there are specific groups for whom these medications are not appropriate. Understanding contraindications is essential for patient safety. If any of the following apply to you, discuss them openly with your healthcare provider before starting GLP-1 therapy.

Medical Contraindications

Personal or family history of medullary thyroid carcinoma (MTC). All GLP-1 receptor agonists carry a boxed warning (the FDA's most serious warning) about the risk of thyroid C-cell tumors. In animal studies, semaglutide, tirzepatide, and liraglutide caused thyroid C-cell tumors in rodents at clinically relevant doses. While this has not been conclusively demonstrated in humans, patients with a personal or family history of medullary thyroid carcinoma should not take GLP-1 medications as a precautionary measure.

Multiple endocrine neoplasia syndrome type 2 (MEN 2). MEN 2 is a rare genetic condition that increases the risk of medullary thyroid carcinoma. Patients with known MEN 2 are contraindicated for all GLP-1 medications due to the theoretical thyroid cancer risk described above.

History of pancreatitis. GLP-1 medications have been associated with cases of acute pancreatitis. While the overall risk appears to be low, patients with a history of pancreatitis (especially recurrent pancreatitis) should use these medications with extreme caution or avoid them entirely. If you develop severe, persistent abdominal pain while taking a GLP-1 medication, seek medical attention immediately as it may indicate pancreatitis.

Severe gastrointestinal disease. Patients with gastroparesis (delayed stomach emptying that is already clinically significant), inflammatory bowel disease, or other severe GI conditions may experience worsening symptoms on GLP-1 medications, since these drugs further slow gastric emptying. Careful evaluation is needed before prescribing in these situations.

History of serious hypersensitivity to the specific medication. If you have had an allergic reaction to semaglutide, tirzepatide, liraglutide, or any of the inactive ingredients in these medications, you should not take the same medication again. In some cases, you may be able to use a different GLP-1 medication that does not contain the ingredient that caused the reaction.

Severe kidney disease. While GLP-1 medications do not require dose adjustment for mild to moderate kidney impairment, patients with severe kidney disease (eGFR below 15 mL/min/1.73m2) or those on dialysis should use these medications cautiously. GI side effects like nausea (see our nausea management guide), vomiting, and diarrhea can worsen dehydration and kidney function in patients with already compromised kidneys.

Diabetic retinopathy (for semaglutide specifically). Semaglutide has been associated with a risk of worsening diabetic retinopathy in patients with existing retinopathy. This is most relevant for patients with type 2 diabetes who have known eye complications. If you have diabetic retinopathy, your provider may recommend additional eye monitoring or may prefer tirzepatide, which has not shown the same association.

Pregnancy and Breastfeeding

GLP-1 medications are contraindicated during pregnancy and should be used with caution in women who may become pregnant. Here are the key considerations.

Pregnancy. GLP-1 medications should be discontinued at least 2 months before planned pregnancy (for semaglutide and tirzepatide, which have long half-lives) or at least 2 weeks before planned pregnancy (for liraglutide, which has a shorter half-life). Animal reproduction studies have shown potential risks including embryo-fetal toxicity and structural abnormalities at high doses. No adequate studies have been conducted in pregnant women. If you become pregnant while taking a GLP-1 medication, discontinue it immediately and contact your healthcare provider.

Breastfeeding. It is not known whether semaglutide, tirzepatide, or liraglutide pass into human breast milk. Animal studies have shown that liraglutide is excreted in milk. Due to the lack of human data, most providers recommend against using GLP-1 medications while breastfeeding. The decision should be made in consultation with your provider, weighing the benefits of breastfeeding and the benefits of treatment against potential risks to the infant.

Fertility. Some women with PCOS experience improved fertility on GLP-1 medications due to weight loss and improved insulin sensitivity. If you are a woman of childbearing age taking a GLP-1 medication, it is important to use reliable contraception and discuss family planning with your provider. Unplanned pregnancy while on GLP-1 therapy requires immediate medical consultation.

Drug Interactions

GLP-1 medications can interact with other medications in ways that may affect safety or efficacy.

Insulin and sulfonylureas. Patients taking insulin or sulfonylurea medications for diabetes are at increased risk of hypoglycemia (low blood sugar) when GLP-1 medications are added. Blood sugar levels should be monitored closely, and the dose of insulin or sulfonylurea may need to be reduced. This is particularly important during the dose titration period.

Oral medications affected by gastric emptying. Because GLP-1 medications slow gastric emptying, they can affect the absorption of oral medications that depend on normal gastric transit times. This is especially relevant for oral contraceptives (birth control pills may be absorbed more slowly or less completely), oral antibiotics, oral thyroid medications (levothyroxine), and other time-sensitive oral medications. If you take oral medications that require precise absorption timing, discuss this with your provider. They may recommend adjusting the timing of your other medications relative to your GLP-1 injection.

Other GLP-1 medications. Never combine two GLP-1 receptor agonists (for example, do not take both Wegovy and Saxenda, or both Ozempic and Wegovy). Using two GLP-1 medications simultaneously increases the risk of severe gastrointestinal side effects and potentially dangerous hypoglycemia in diabetic patients.

Warfarin. Patients taking warfarin should have their INR (blood clotting levels) monitored more frequently when starting or changing the dose of a GLP-1 medication. The slowed gastric emptying may affect warfarin absorption and change its effectiveness.

When Other Approaches Are Better

GLP-1 medications are not the right solution for everyone. In some situations, other approaches may be more appropriate.

BMI under 25 (normal weight). If your BMI is in the normal range, GLP-1 medications are not appropriate regardless of your cosmetic preferences. Weight management medications are designed to treat a medical condition (obesity), not to help people at a healthy weight become thinner. If you are at a normal weight and dissatisfied with your body, a conversation with your healthcare provider about body image, nutrition, and fitness may be more productive.

Active eating disorder. Patients with active anorexia nervosa, bulimia nervosa, or binge eating disorder should not start GLP-1 medications without specialized psychiatric evaluation and monitoring. While some research suggests that GLP-1 medications may eventually play a role in treating certain eating disorders, this is an active area of investigation and not a standard treatment. The appetite-suppressing effects of GLP-1 medications could be dangerous in patients with restrictive eating disorders.

Unwillingness to make lifestyle changes. GLP-1 medications are most effective when combined with nutritional changes and physical activity. Patients who are unwilling or unable to make any lifestyle modifications will likely see reduced results and may experience more difficulty with weight maintenance long-term. This does not mean you need to overhaul your entire life before starting medication, but a willingness to work on nutrition, exercise, and behavioral habits is important for optimal outcomes.

When bariatric surgery may be more appropriate. For patients with BMI of 40 or higher (or BMI of 35 or higher with serious comorbidities) who have not responded adequately to medical weight management, bariatric surgery may produce greater and more durable weight loss. Surgical options such as gastric sleeve or gastric bypass have decades of long-term outcome data and can produce weight loss of 25% to 35% of body weight. The choice between medication and surgery is deeply personal and should be discussed thoroughly with your healthcare team.

Financial hardship. If the cost of GLP-1 medication would create significant financial stress, and cheaper alternatives are available and clinically appropriate, those alternatives should be considered first. Non-GLP-1 prescription weight loss medications (such as phentermine, phentermine-topiramate, bupropion-naltrexone, or orlistat) are available at much lower costs and may be sufficient for patients who need modest weight loss. Compounded GLP-1 medications at $150 to $500 per month offer a middle ground between brand-name GLP-1 drugs and less expensive alternatives.

Frequently Asked Questions About GLP-1 Weight Loss Medications

Below are answers to the questions we hear most often from patients considering or currently taking GLP-1 medications for weight loss. For questions about whether you might qualify, review the eligibility criteria section above or use our BMI requirements guide.

Understanding the Science Behind GLP-1 Medications

To make a truly informed decision about GLP-1 therapy, it helps to understand how these medications work at a biological level. This section is for readers who want a deeper understanding of the mechanisms driving their weight loss results.

What Is GLP-1 and Why Does It Matter?

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone produced by L-cells in the lining of your small intestine. When you eat a meal, these cells release GLP-1 into your bloodstream within minutes. The hormone then travels to multiple organs and tissues, triggering a cascade of metabolic effects.

In the pancreas, GLP-1 stimulates insulin secretion in a glucose-dependent manner. This means it helps your pancreas release the right amount of insulin when blood sugar is elevated, but does not cause excessive insulin release when blood sugar is normal. This glucose-dependent action is one reason why GLP-1 medications rarely cause dangerous hypoglycemia when used alone (without insulin or sulfonylureas).

In the brain, GLP-1 acts on receptors in the hypothalamus and brainstem, two regions critical for appetite regulation and energy balance. Natural GLP-1 reduces appetite, decreases food reward signaling, and promotes feelings of fullness. However, natural GLP-1 has an extremely short half-life of only about 2 minutes. It is rapidly broken down by an enzyme called DPP-4 (dipeptidyl peptidase-4). This means the appetite-suppressing effects of your body's own GLP-1 are brief and relatively modest.

GLP-1 medications are engineered to resist DPP-4 breakdown, giving them half-lives of hours to days rather than minutes. Semaglutide has a half-life of approximately 7 days, which is why it can be administered once weekly. Liraglutide has a half-life of approximately 13 hours, requiring daily administration. This extended duration of action allows pharmaceutical GLP-1 to produce sustained appetite suppression and metabolic effects that natural GLP-1 cannot achieve on its own.

In the stomach, GLP-1 slows gastric emptying, meaning food moves from your stomach to your small intestine more slowly. This contributes to prolonged feelings of fullness after meals and helps explain why many patients on GLP-1 medications report being satisfied with much smaller portions than they previously consumed.

The Dual and Triple Agonist Approach

The success of GLP-1 receptor agonists led researchers to explore whether activating additional incretin and metabolic hormone receptors could produce even greater benefits. This research has yielded two important developments: dual agonists and triple agonists.

Dual GLP-1/GIP agonism (tirzepatide). Glucose-dependent insulinotropic polypeptide (GIP) is another incretin hormone released after meals. For decades, GIP was primarily studied in the context of diabetes and was actually thought to promote fat storage. However, more recent research revealed that GIP receptor activation in the brain produces additional appetite-suppressing effects and may increase energy expenditure. Tirzepatide activates both GLP-1 and GIP receptors, and the clinical data strongly suggests that this dual approach produces greater weight loss than GLP-1 activation alone. The exact mechanisms are still being studied, but it appears that GIP and GLP-1 have complementary and combined effects on appetite, metabolism, and fat use.

Dual GLP-1/glucagon agonism (survodutide). Glucagon is a hormone that raises blood sugar and promotes fat breakdown. While this might seem counterproductive for weight loss (since elevated blood sugar is undesirable), glucagon receptor activation also increases energy expenditure and promotes the breakdown of stored fat. By combining GLP-1's appetite suppression with glucagon's energy-burning effects, dual GLP-1/glucagon agonists may offer a different metabolic profile than GLP-1/GIP combinations. Early clinical data is promising, though these medications are still in development.

Triple GLP-1/GIP/glucagon agonism (retatrutide). The triple agonist approach combines all three mechanisms: GLP-1 for appetite suppression and insulin regulation, GIP for enhanced appetite control and metabolic effects, and glucagon for increased energy expenditure and fat metabolism. Phase 2 data for retatrutide showed the most impressive weight loss results of any pharmaceutical agent tested to date, suggesting that targeting multiple metabolic pathways simultaneously may be the future of obesity pharmacotherapy.

How GLP-1 Changes Your Relationship with Food

One of the most remarkable aspects of GLP-1 therapy, and one that is not fully captured by clinical trial weight loss numbers, is how these medications change the subjective experience of hunger, cravings, and food-related thoughts.

Neuroimaging studies have shown that GLP-1 receptor agonists reduce activation in brain regions associated with food reward and craving, including the insula, amygdala, and orbitofrontal cortex. In practical terms, this means that many patients report a dramatic reduction in what is sometimes called "food noise," the constant, intrusive thoughts about food that many people with obesity experience throughout the day.

Patients frequently describe this change using phrases like "food just does not occupy my thoughts the way it used to," or "I can walk past a bakery without feeling pulled inside," or "for the first time in my life, I can take two bites of dessert and feel genuinely satisfied." These experiences reflect genuine neurochemical changes in how the brain processes food-related stimuli.

This reduction in food preoccupation has psychological benefits beyond weight loss. Many patients report reduced anxiety around food, improved ability to focus on work and relationships, less guilt and shame associated with eating, and an overall improvement in quality of life that goes beyond what the number on the scale would suggest.

Research is now exploring whether GLP-1 medications may also reduce cravings for other rewarding substances, including alcohol. Some clinical observations and early trial data suggest that patients on GLP-1 medications report reduced alcohol consumption and reduced desire to drink. Formal clinical trials are underway to investigate this potential application.

Understanding Body Composition Changes

Weight loss is not a single phenomenon. When you lose weight through any method, the lost weight consists of several tissue types, primarily fat mass and lean mass (which includes muscle, bone, water, and organ tissue). The ratio of fat loss to lean loss matters enormously for long-term health and metabolic function.

In GLP-1 clinical trials using body composition analysis (typically DXA scans), the average breakdown of weight loss has been approximately 60-75% fat mass and 25-40% lean mass. This ratio is similar to what is seen with caloric restriction alone and somewhat less favorable than what is achieved with bariatric surgery (which tends to preserve slightly more lean mass relative to fat loss).

The lean mass loss component is the primary reason why protein intake and resistance training are so heavily emphasized during GLP-1 therapy. Muscle is metabolically active tissue, meaning it burns calories even at rest. Losing too much muscle lowers your resting metabolic rate, making it harder to maintain weight loss long-term and reducing functional strength and physical capacity.

Some promising research suggests that newer dual and triple agonist medications may produce more favorable body composition changes than pure GLP-1 agonists. Specifically, the glucagon component of certain pipeline drugs may preferentially promote fat loss while sparing lean tissue, though this remains an area of active investigation.

Regardless of which GLP-1 medication you take, the combination of adequate protein intake (60 to 100 grams daily) and regular resistance training (at least twice per week) is the most effective strategy currently available for maximizing fat loss while preserving muscle mass during treatment.

Preparing for Your GLP-1 process - A Practical Checklist

Starting GLP-1 therapy is a significant decision, and proper preparation sets the stage for the best possible outcomes. Below is a comprehensive preparation checklist that covers everything from the practical logistics to the mindset shifts that support success.

Before Your First Appointment

Gather your medical records. If you have medical records from your primary care provider, endocrinologist, or other specialists, compile the key documents. Relevant records include recent lab work (ideally within the past 12 months), documentation of weight-related diagnoses (diabetes, hypertension, sleep apnea, etc.), a list of all current prescription medications and supplements, records of previous weight loss attempts (programs, medications, surgical consultations), and any relevant imaging or diagnostic reports. Having this information readily available simplifies the consultation process and reduces the chance of delays due to missing documentation.

Check your insurance coverage. Before your appointment, call your insurance company or check your plan's formulary online to understand whether GLP-1 weight loss medications are covered. Ask specifically about Wegovy, Zepbound, and Saxenda. Find out if prior authorization is required, what documentation they need, and whether there are step therapy requirements. If your insurance does not cover GLP-1 medications, research compounded options and their costs so you can discuss affordable alternatives with your provider.

Set realistic expectations. Go into your consultation understanding that GLP-1 medications are powerful but not perfect. Not every patient achieves the average weight loss seen in clinical trials. Side effects are common, especially in the first few weeks. Weight loss takes time and requires patience through the titration period. The medication works best when combined with lifestyle changes. Setting realistic expectations helps prevent discouragement and supports long-term adherence.

Prepare your questions. Write down any questions you have for your provider. Common questions include: which medication do you recommend for my situation and why? What side effects should I watch for, and when should I contact you? How will we monitor my progress and adjust treatment? What dietary changes should I prioritize from day one? How long do you typically recommend patients stay on GLP-1 medication? What happens if this medication does not work for me?

Setting Up Your Home Environment

Kitchen preparation. Before your medication arrives, stock your kitchen with protein-rich foods that will become staples of your new eating pattern. Good options include Greek yogurt, cottage cheese, eggs, lean chicken or turkey, fish, protein powder, nuts and nut butters, legumes, and tofu. Clear out or relocate foods that you know trigger overeating. This is not about deprivation but about making the healthier choice the easier choice, especially during the early weeks when your appetite changes may be dramatic.

Hydration setup. Purchase a large water bottle (32 to 40 ounces) that you can carry with you throughout the day. Staying hydrated is critical for managing GLP-1 side effects and supporting the metabolic processes of weight loss. Having water readily accessible makes it much easier to meet your daily intake goals of 64 to 100 ounces.

Medication storage. GLP-1 medications require refrigeration (36 to 46 degrees Fahrenheit or 2 to 8 degrees Celsius). Designate a spot in your refrigerator for your medication. If you travel frequently, invest in a small insulated medication travel case that can keep your injection pens at the proper temperature for 12 to 24 hours. Never freeze GLP-1 medications, and never use medication that has been left at room temperature for extended periods.

Exercise equipment. You do not need an elaborate home gym, but having some basic resistance training equipment makes it much easier to build a consistent exercise routine. A set of adjustable dumbbells, a few resistance bands, and a yoga mat are sufficient for an effective home workout program. If you prefer gym workouts, consider signing up for a membership before you start medication so that it becomes part of your routine from the beginning.

Mental and Emotional Preparation

Reframe your relationship with the scale. Many people starting GLP-1 therapy have a complicated history with their weight and with the scale. It is helpful to approach the scale as one data point among many, not as a judgment of your worth or success. Some weeks the number will go down. Some weeks it will stay the same or even go up slightly, even if you are doing everything right. Body weight fluctuates due to water retention, hormonal cycles, sodium intake, exercise timing, and many other factors that have nothing to do with fat loss. Weigh yourself no more than once per week at the same time of day, and focus equally on non-scale measures of progress like how your clothes fit, how your energy levels feel, what your lab results show, and how your physical capacity improves.

Build your support network. Tell the people closest to you about your decision to start GLP-1 therapy. You do not owe anyone an explanation, but having supportive people around you makes the process easier. If you have a partner who does the cooking, discuss the dietary changes you plan to make. If you have friends who are also interested in weight management, consider creating accountability partnerships. If you prefer privacy, online communities of GLP-1 patients can provide anonymous support and practical advice from people who understand exactly what you are experiencing.

Plan for side effects. The first few weeks of GLP-1 therapy often involve nausea, fatigue, and digestive changes. Plan your start date accordingly. Some patients prefer to begin their medication on a Friday so they have the weekend to adjust before returning to work. Keep bland, easily digestible foods on hand (crackers, broth, ginger tea, rice) for days when nausea is bothersome. Know that these side effects are temporary for most people and typically improve significantly within 4 to 8 weeks.

Define your long-term goals. Weight loss is the obvious goal, but take some time to think about what meaningful changes you hope to see beyond the number on the scale. Do you want to reduce or eliminate medications for blood pressure or diabetes? Do you want to be more active with your children or grandchildren? Do you want to reduce joint pain so you can enjoy activities you have given up? Do you want to improve your cardiovascular risk profile? Having these concrete, personal goals gives you something to focus on during the inevitable moments when motivation wanes, and they provide a more sustainable source of motivation than the scale alone.

Taking the time to prepare physically, logistically, and mentally before starting GLP-1 therapy pays dividends throughout your treatment process. The patients who achieve the best long-term results are not necessarily those with the best genetics or the strongest willpower. They are the ones who approached treatment with preparation, realistic expectations, and a commitment to making the most of this powerful medical tool.

Taking the Next Step

GLP-1 medications have fundamentally changed what is possible for people living with obesity. For the first time, there are FDA-approved pharmaceutical tools that can produce weight loss comparable to bariatric surgery in some patients, with a favorable safety profile and the convenience of a weekly injection.

But these medications are not magic. They are medical tools that work best as part of a comprehensive approach to weight management. The patients who achieve the best results are those who combine medication with adequate protein intake, regular resistance training, quality sleep, proper hydration, and sustainable behavioral changes.

If you are considering GLP-1 therapy, the most important step you can take right now is to have a conversation with a qualified healthcare provider. Whether that is your primary care doctor, an endocrinologist, an obesity medicine specialist, or a licensed telehealth provider, getting a professional evaluation is the starting point for everything that follows.

Here is a summary of what we covered in this guide:

• Eligibility: You may qualify with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like type 2 diabetes, high blood pressure, or high cholesterol.
• Medication options: Wegovy (semaglutide 2.4mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0mg) are the three FDA-approved brand-name options. Compounded semaglutide and tirzepatide offer significantly lower-cost alternatives through licensed pharmacies.
• Choosing a medication: The right choice depends on your health profile, insurance coverage, budget, and personal preferences. Tirzepatide produces the highest average weight loss, semaglutide has the most clinical evidence and proven cardiovascular benefits, and compounded options offer the best affordability.
• The process: From consultation to first injection takes as little as 5 to 10 days for cash-pay patients using telehealth and compounded medications, or 2 to 4 weeks when going through insurance prior authorization.
• Insurance: Coverage is expanding but inconsistent. Approximately 40-50% of commercial plans now cover GLP-1 weight loss medications. Medicare coverage has expanded following the TREAT Act. Prior authorization is almost always required.
• What to expect: Most patients lose 2-5% of body weight in the first two months, 8-15% by month 6, and 12-22% by month 12. Results vary by medication and individual response.
• Maximizing results: Prioritize protein (60-100g daily), resistance training, quality sleep, hydration, and sustainable behavioral changes.
• Contraindications: GLP-1 medications are not appropriate for everyone. Key contraindications include personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy, and active pancreatitis.

Ready to explore your options? Browse GLP-1 treatment programs on FormBlends, or start with our comparison of the best online GLP-1 providers in 2026.

For more in-depth information on specific topics covered in this guide, explore these related resources:

• GLP-1 Medications Weight Loss Guide
• Complete Semaglutide Weight Loss Guide
• GLP-1 Insurance Coverage Complete Guide 2026
• GLP-1 Cost Without Insurance Complete Guide 2026
• What BMI Do You Need for Weight Loss Medication?
• Semaglutide Programs
• Tirzepatide Programs